Chronic lymphocytic leukaemia: Could immunological tolerance mechanisms be the origin of lymphoid neoplasms?

Immunology

Volumn 142, Issue 4, 2014, Pages 536-550

  García Muñoz, Ricardo ^a   Llorente, Luis ^b  

^a HOSPITAL SAN PEDRO   (Spain)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Anergy; Chronic lymphocytic leukaemia; Clonal selection theory; Immunological tolerance; Receptor editing

Indexed keywords

B LYMPHOCYTE RECEPTOR; HELIX LOOP HELIX PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; NOTCH1 RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR EBF; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG;

ALLELIC EXCLUSION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; BONE MARROW; CANCER THERAPY; CELL MATURATION; CELL PROLIFERATION; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CLONE; FOLLICULAR LYMPHOMA; GENE LOCUS; GENETIC DAMAGE; GENOMIC INSTABILITY; GERMINAL CENTER; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE FUNCTION; MEMORY CELL; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SOMATIC HYPERMUTATION; SOMATIC MUTATION; TRISOMY 12;

ANERGY; CHRONIC LYMPHOCYTIC LEUKAEMIA; CLONAL SELECTION THEORY; IMMUNOLOGICAL TOLERANCE; RECEPTOR EDITING;

B-LYMPHOCYTES; HUMANS; IMMUNE TOLERANCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84904066355     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12285     Document Type: Article

References (158)

1. Herreros B, Sanchez-Agulere A, Piris MA. Lymphoma microenvironment. In: Magrath IT, Bathia K, Boffetta P, Dearden C, Diehl V, Gascoyne RD, Muller-Hermelink HK, Potter M, Rohatiner A, eds. The Lymphoid Neoplams, 3rd edn. London, UK: Oxford University Press, 2010:1552.
2. García-Muñoz R, Galiacho VR, Llorente L. Immunological aspects in chronic lymphocytic leukemia (CLL) development. Ann Hematol 2012; 91:981-96.
3. García-Muñoz R, Panizo C, Bendandi M, Llorente L. Autoimmunity and lymphoma: is mantle cell lymphoma a mistake of the receptor editing mechanism? Leuk Res 2009; 33:1437-9.
4. Luning Prak ET, Monestier M, Eisenberg RA. B cell receptor editing in tolerance and autoimmunity. Ann N Y Acad Sci 2011; 1217:96-121.
5. Burnet M. Tolerance and paralysis. In: Sir Macfarlane Burnet Auto-Immunity and Auto-Immune Disease, 1st edn. Letchworth, UK: The Garden City Press Limited, 1972:59.
6. Wang JH, Alt FW, Gostissa M et al. Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching. J Exp Med 2008; 205:3079-90.
7. Kobrin C, Cha SC, Qin H et al. Molecular analysis of light-chain switch and acute lymphoblastic leukemia transformation in two follicular lymphomas: implications for lymphomagenesis. Leuk Lymphoma 2006; 47:1523-34.
8. Yonetani N, Ueda C, Akasaka T, Nishikori M, Uchiyama T, Ohno H. Heterogeneous breakpoints on the immunoglobulin genes are involved in fusion 5' region of BCL-2 in B cell tumors. Jpn J Cancer Res 2001; 92:933-40.
9. Herve M, Xu K, Ng YS, Wardemann H, Albesiano E, Messmer BT, Chiorazzi N, Meffre E. Unmutated and mutated chronic lyphocytic leukemia derive from self reactive B cell precursors despite expressing antibody reactivity. J Clin Invest 2005; 115:1636-43.
10. Mockridge CI, Potter KN, Wheatley I, Neville LA, Packham G, Stevenson FK. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007; 109:4424-31.
11. Papakonstantinou N, Ntoufa S, Chartomatsidou E et al. Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. Mol Med 2013; 19:115-23.
12. Cappione A 3rd, Anolik JH, Pugh-Bernard A, Barnard J, Dutcher P, Silverman G, Sanz I. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 2005; 115:3205-16.
13. Pugh-Bernard AE, Silverman GJ, Cappione AJ, Villano ME, Ryan DH, Insel RA, Sanz I. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J Clin Invest 2001; 108:1061-70.
14. Matejuk A, Beardall M, Xu Y, Tian Q, Phillips D, Alabyev B, Mannoor K, Chen C. Exclusion of natural autoantibody-producing B cells from IgG memory B cell compartment during T cell-dependent immune response. J Immunol 2009; 182:7634-43.
15. + memory B cell development. J Exp Med 2006; 203:393-400.
16. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2011; 117:1781-91.
17. -. J Exp Med 2011; 208:67-80.
18. Seifert M, Sellmann L, Bioehdorn J, Wein F, Stilgenbauer S, Dürig J, Küppers R. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med 2012; 209:2183-98.
19. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004; 103:4389-95.
20. DiLillo DJ, Weinberg JB, Yoshizaki A et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia 2013; 27:170-82.
21. Klein U, Tu Y, Stolovitzky GA et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194:1625-38.
22. Caligaris-Cappio F. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 1996; 87:2615-20.
23. Rosenwald A, Alizadeh AA, Widhopf G et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194:1639-47.
24. Kulis M, Heath S, Bibikova M et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet 2012; 44:1236-42.
25. Hoogeboom R, Wormhoudt TA, Schipperus MR, Langerak AW, Dunn-Walters DK, Guikema JE, Bende RJ, van Noesel CJ. A novel chronic lymphocytic leukemia subset expressing mutated IGHV3-7 encoded rheumatoid factor B cell receptors that are functionally proficient. Leukemia 2013; 27:738-40.
26. Hoogeboom R, van Kessel KP, Hochstenbach F et al. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J Exp Med 2013; 210:59-70.
27. Hamblin T, Hamblin A. Chronic lymphocytic leukemia. In: Saba HI, Mufti GJ, eds. Advances in Malignant Hematology, 1st edn. Oxford: Blackwell Publishing Ltd, 2011:211.
28. Agathangelidis A, Darzentas N, Hadzidimitriou A, et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012; 119:4467-75.
29. Forconi F, Potter KN, Wheatley I et al. The normal IGHV1-69 derived B cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood 2010; 115:71-7.
30. H genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 1997; 89:4153-60.
31. Ghia P, Stamatopoulos K, Belessi C et al. Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005; 105:1678-85.
32. + chronic lymphocytic leukmemia B cells. J Exp Med 1995; 181:1507-17.
33. Potter KN, Mockridge CL, Neville L et al. Structural and functional features of the B cell receptor in IgG-positive chronic lymphocytic leukemia. Clin Cancer Res 2006; 12:1672-9.
34. Ghiotto F, Fais F, Valetto A et al. Remarably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 2004; 113:1008-16.
35. Ntoufa S, Vardi A, Papakonstantinou N et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol Med 2012; 18:1281-91.
36. Tobin G, Thunberg U, Johnson A et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vλ2-14 gene use and homologous CDR3s: implication recognition of a common antigen epitope. Blood 2003; 101:4952-7.
37. Stamatopoulos K, Belessi C, Hadzidimitriou A et al. Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. Blood 2005; 106:3575-83.
38. Chu CC, Catera R, Hatzi K et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 2008; 112:5122-9.
39. Catera R, Silverman GJ, Hatzi K et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008; 14:665-74.
40. Lanemo Myhrinder A, Hellqvist E et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008; 111:3838-48.
41. Sthoeger ZM, Wakai M, Tse DB et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med 1989; 169:255-68.
42. Efremov DG, Ivanovski M, Batista FD, Pozzato G, Burrone OR. IgM-producing chronic lymphocytic leukemia cells undergo immunoglobulin isotype-switching without acquiring somatic mutations. J Clin Invest 1996; 98:290-8.
43. H genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94:1848-54.
44. Damle RN, Wasil T, Fais F et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94:1840-7.
45. Muller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stain H. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, eds. WHO Clasification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 2008:180-2.
46. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003; 301:1374-7.
47. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenszweig MC. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005; 201:703-11.
48. Halverson R, Torres RM, Pelanda R. Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nat Immunol 2004; 5:645-50.
49. Zhang Z, Zemlin M, Wang YH et al. Contribution of VH gene replacement to the primary B cell repertoire. Immunity 2003; 19:21-31.
50. Wardemann H, Hammersen J, Nussenzeig MC. Human autoantibody silencing by immunoglobulin light chains. J Exp Med 2004; 200:191-9.
51. Duty JA, Szodoray P, Zheng NY et al. Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med 2009; 206:139-51.
52. Chan TD, Brink R. Affinity-based selection and the germinal center response. Immunol Rev 2012; 247:11-23.
53. Weistein JS, Hernandez SG, Craft J. T cells that promote B-cell maturation in systemic autoimmunity. Immunol Rev 2012; 247:160-71.
54. + memory B cells. Immunity 2007; 26:205-13.
55. Cadera EJ, Wan G, Amin RH, Nolla H, Lenardo MJ, Schlissel MS. NF-κB activity marks cells engaged in receptor editing. J Exp Med 2009; 206:1803-16.
56. Meffre E, Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 2008; 20:632-8.
57. Isnardi I, Ng YS, Srdanovic I et al. IRAK-4- and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 2008; 29:746-57.
58. Isnardi I, Ng YS, Menard L et al. Complement receptor 2/CD21-human naive B cells contain mostly autoreactive unresponsive clones. Blood 2010; 115:5026-36.
59. Kikushige Y, Ishikawa F, Miyamoto T et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 2011; 20:246-59.
60. Rassenti LZ, Kipps TJ. Lack of allelic exclusion in B cell chronic lymphocytic leukemia. J Exp Med 1997; 185:1435-45.
61. Dühren-von Minden M, Übelhart R, Schneider D et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signaling. Nature 2012; 489:309-12.
62. Köhler F, Hug E, Eschbach C, Meixlsperger S, Hobeika E, Kofer J, Wardemann H, Jumaa H. Autoreactive B cell receptors mimic autonomous pre-B cell receptor signaling and induce proliferation of early B cells. Immunity 2008; 29:912-21.
63. van Loo PF, Dingjan GM, Maas A, Hendriks RW. Surrogate-light-chain silencing is not critical for the limitation of pre-B cell expansion but is for the termination of constitutive signaling. Immunity 2007; 27:468-80.
64. Meixlsperger S, Köhler F, Wossning T, Reppel M, Müschen M, Jumaa H. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity 2007; 26:323-33.
65. Hadzidimitriou A, Darzentas N, Murray F et al. Evidence for the significant role of immunoglobulin light chains in antigen recognition and selection in chronic lymphocytic leukemia. Blood 2009; 113:403-11.
66. Gauthier L, Rossi B, Roux F, Termine E, Schiff C. Galectin-1 is a stromal cell ligand of the pre-B cell receptor (BCR) implicated in synapse formation between pre-B and stromal cells and in pre-BCR triggering. Proc Natl Acad Sci USA 2002; 99:13014-9.
67. Croci DO, Morande PE, Dergan-Dylon S et al. Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1. Leukemia 2013; 27:1413-6.
68. Coelho V, Krysov S, Steele A et al. Identification in CLL of circulating intraclonal subgrups with varying B cell receptor expression and function. Blood 2013; 122:2664-72.
69. Klippel JH, Crofford LJ, Stone JH, Weyland CM, eds. Primer on the Rheumatic Diseases, 12th edn. Atlanta, GA, USA: Arthritis Foundation, 2001.
70. Muzio M, Apollonio B, Scielzo C, Frenquelli M, Vandoni I, Boussiotis V, Caligaris-Cappio F, Ghia P. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 2008; 112:188-95.
71. Apollonio B, Scielzo C, Bertilaccio MT et al. Targeting B cell anergy in chronic lymphocytic leukemia. Blood 2013; 121:3879-88.
72. Negro R, Gobessi S, Longo PG, He Y, Zhang ZY, Laurenti L, Efremov DG. Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT. Blood 2012; 119:6278-87.
73. Menard L, Saadoun D, Isnardi I et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest 2011; 121:3635-44.
74. Rawstron AC, Bennet FL, O'Connor SJM et al. Monoclonal B cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008; 359:575-83.
75. Ladgren O, Albitar M, Wanlong M et al. B cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 2009; 360:659-67.
76. Henriques A, Rodriguez-Caballero A, Nieto WG et al. Combined patterns of IGHV repertoire and cytogenetic/molecular alterations in monoclonal B cell lymphocytosis versus chronic lymphocytic leukemia. PLoS One 2013; 8:e67751.
77. Fulci V, Chiaretti S, Goldoni M et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007; 109:4944-51.
78. Calin GA, Liu CG, Sevignani C et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101:11755-60.
79. Puente XS, Pinyol M, Quesada V et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475:101-105.
80. Rosati E, Sabatini R, Rampino G et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood 2009; 113:856-65.
81. Fabbri G, Rasi S, Rossi D et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011; 208:1389-401.
82. Rossi D, Rasi S, Fabbri G et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119:521-9.
83. Quesada V, Conde L, Villamor N et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011; 44:47-52.
84. Wang L, Lawrence MS, Wan Y et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365:2497-506.
85. Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ, Pekarsky Y, Croce CM. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012; 119:329-31.
86. Balatti V, Lerner S, Rizzotto L et al. Trisomy 12 CLLs progress through NOTCH1 mutations. Leukemia 2013; 27:740-3.
87. Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910-6.
88. Shanafelt TD, Witzing TE, Fink SR et al. Prospective evolution during long-term follow-up of patients with untreated early stage chronic lymphocytic leukemia. J Clin Oncol 2006; 24:4634-41.
89. Murrray F, Darzentas N, Hadzidimitrioy A et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 2008; 111:1524-33.
90. Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukemia. Br Med Bull 2008; 87:49-62.
91. García-Muñoz R, García DK, Roldan-Galiacho V, Merchante-Andreu M, Campeny-Najara A, Rabasa P. Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with Rituximab-Bendamustine. Ann Hematol 2014; 93:699-702.
92. Lotz M, Ranheim E, Kipps TJ. Transforming growth factor β as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 1994; 179:999-1004.
93. Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118:2427-37.
94. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012; 120:1412-21.
95. Weiss L, Melchardt T, Eagle A, Grabmer C, Greil R, Tinhofer I. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 2009; 27:e5-6.
96. D'Arena G, D'Auria F, Simeon V et al. A shorter time to the first treatment may be predicted by the absolute number of regulatory T cells in patients with Rai stage 0 chronic lymphocytic leukemia. Am J Hematol 2012; 87:628-31.
97. Lad DP, Varma S, Varma N, Sachdeva MU, Bose P, Malhotra P. Regulatory T cells in B cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias. Leuk Lymphoma 2013; 54:1012.
98. Sampalo A, Brieva JH. Humoral immunodeficiency in chronic lymphocytic leukemia: role of CD95/95L in tumoral damage and escape. Leuk Lymphoma 2002; 43:881-4.
99. Gilling CE, Mittal AK, Chaturvedi NK et al. Lymph node induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1. Br J Haematol 2012; 158:216-31.
100. Riches JC, Davies JK, McClanahan F, Fatah R, Igbal S, Agrawal S, Ramsay AG, Gribben JG. T cells from CLL patients exhibit features of T cell exhaustion but retain capacity for cytokine production. Blood 2013; 121:1612-21.
101. + replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin Cancer Res 2012; 18:678-87.
102. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008; 2008:450-6.
103. Kay NE, Zarling JM. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with deficiency of azyrophilic cytoplasmic granules in putative NK cells. Blood 1984; 63:305-9.
104. Itala M, Vainio O, Remes K. Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia. Eur J Haematol 1996; 57:46-53.
105. Schlesinger M, Broman I, Lugassy G. The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia 1996; 10:1509-13.
106. Caligaris-Cappio F. Chronic lymphocytic leukemia "Cinderella" is becoming a star. Mol Med 2009; 15:67-9.
107. Tripodo C, Porcasi R, Guarnotta C, Ingrao S, Campisi V, Florena AM, Franco V. C1q production by bone marrow stromal cells. Scand J Immunol 2007; 65:308-9.
108. Espinoza CR, Feeney AJ. The extent of histone acetylation correlates with the differential rearrangement frequency of individual VH genes in pro-B cells. J Immunol 2005; 175:6668-75.
109. Oppezzo P, Dumas G, Lalanne AI, Peyelle-Brogard B, Magnac C, Pritsch O, Dighiero G, Vuillier F. Different isoforms of BASAP regulate expression of AID in normal and chronic lymphocytic leukemia B cells. Blood 2005; 105:2495-503.
110. Rothenberg EV, Telfer JC, Anderson MK. Transcriptional regulation of lymphocyte lineage commitment. BioEssays 1999; 21:726-42.
111. Kardava L, Yang Q, St Leger A, Foon KA, Lentzch S, Vallejo AN, Milcarek C, Borghesi L. The B lineage transcription factor E2A regultes apoptosis in chronic lymphocytic leukemia (CLL) cells. Int Immunol 2001; 23:375-84.
112. Quong MW, Martensson A, Langerak AW, Rivera RR, Nemazee D, Murre C. Receptor editing and marginal zone B cell development are regulated by the helix-loop-helix Protein, E2A. J Exp Med 2004; 199:1101-12.
113. Lin YC, Jhunjhunwala S, Benner C et al. A global network of transcription factors, involving E2A, EBF1 and Foxp1 that orchestrates the B cell fate. Nat Immunol 2010; 11:635-43.
114. Klenle D, Benner A, Läufle C et al. Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. Haematologica 2010; 95:102-9.
115. Lloberas J, Soler C, Celada A. The key role of PU.1/SPI-1 in B cells, myeloid cells and macrophages. Immunol Today 1999; 20:184.
116. Bassuk AG, Leiden JM. The role of ETS transcription factors in the development and function of the mammalian immune system. Adv Immunol 1997; 64:65.
117. Mankai A, Bordron A, Renaudineau Y, Martins-Carvalho C, Takahashi S, Ghedira I, Berthou C, Youinou P. Purine-rich box-1 mediated reduced expression of CD20 alters rituximab induced lysis of chronic lymphocytic leukemia B cells. Cancer Res 2008; 68:7512-9.
118. Iwasaki H, Somoza C, Shigematsu H et al. Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood 2005; 106:1590.
119. Polli M, Dakic A, Light A, Wu L, Tarlingon DM, Nutt SL. The development of functional B lymphocytes in conditional PU.1 knock-out mice. Blood 2005; 106:2083.
120. Medina KL, Ponguabala JM, Reddy KL et al. Assembling a gene regulatory network for specification of the B cell fate. Dev Cell 2004; 7:607-17.
121. Yuki H, Ueno S, Tatetsu H et al. Pu.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells. Blood 2013; 121:962-70.
122. Travis A, Amsterdam A, Belangeer C, Grosschedl R. LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T cell receptor α enhance function. Genes Dev 1991; 5:880-94.
123. Raya T, O'Riordan M, Okamura R, Devaney E, Willert K, Nusse R, Grosschedl R. Wnt signaling regultes B lymphocyte proliferation through a LEF-1 dependent mechanism. Immunity 2000; 13:15-24.
124. Gutierrez A Jr, Tscumper RC, Wu X et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B cell lymphocytosis. Blood 2010; 116:2975-83.
125. Gutierrez A Jr, Arendt BK, Tschumper RC, Kay NE, Zent CS, Jelinek DF. Differentiation of chronic lymphocytic leukemia B cells into immunoglobulin secreting cells decreases LEF-1 expression. Plos One 2011; 6:e26056.
126. Jansen K, Rother MB, Brusletto BS, Olstad OK, Dalsbotten Aass HC, Van Zelm MC, Kierulf P, Gautvik KM. Increased ID2 levels in adult precursor B cells as compared with children is associated with impaired Ig locus contraction and decreased bone marrow output. J Immunol 2013; 191:1210-9.
127. Husson H, Carideo EG, Neubeg D et al. Gene expression profiling lymphoma and normal germinal center B cells using cDNA arrays. Blood 2002; 99:282-9.
128. Mayers G, Ng YS, Bannock JM et al. Activation-induced cytidine deaminase (AID) is required for B cell tolerance in humans. Proc Natl Acad Sci USA 2011; 108:11554-9.
129. Durandy A, Cantaert T, Kracker S, Meffre E. Potential roles of activation-induced cytidine deaminase in promotion or prevention of autoimmunity in humans. Autoimmunity 2013; 46:148-56.
130. Oppezzo P, Vuillier F, Vasconcelos Y, Dumas G, Magnac C, Payelle-Brogard B, Pritsch O, Dighiero G. Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation. Blood 2003; 101:4029-32.
131. Patten PE, Chu CC, Albesiano E et al. IGHV-unmuteted and IGHV mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. Blood 2012; 120:4802-11.
132. Hu H, Wang B, Borde M, Nardone J, Maika S, Allred L, Tucker PW, Rao A FOXP1 is an essential transcriptional regulator of B cell development. Nat Immunol 2006; 7:819-26.
133. Chen Z, Xiao Y, Zhang J et al. Transcription factors E2A, FOXO1 and FOXP1 regulate recombination activating gene expression in cancer cells. PLoS One 2011; 6:e20475.
134. Sargardoy A, Martinez-Ferrandis JL, Roa S et al. Downregulation of FOXP1 is required during germinal center B cell function. Blood 2013; 121:4311-20.
135. Karnowski A, Cao C, Matthias G, Carotta S, Corcoran LM, Martensson IL, Skok JA, Matthias P. Silencing and nuclear repositioning of the λ5 gene locus at the pre-B cell stage requires Aiolos and OFB-1. PLoS One 2008; 3:e3568.
136. Sun J, Matthias G, Mihatsch MJ, Georgopoulos K, Matthias P. Lack of the transcriptional coactivator OBF-1 prevents the development of systemic lupus erythematosus like phenotypes in Aiolos mutant mice. J Immunol 2003; 170:1699-706.
137. Billot K, Soeur J, Chereau F et al. Deregulation of Aiolos expression in chronic lymphcytic leukemia is associated with epigenetic modifications. Blood 2011; 117:1917-27.
138. Nagy M, Chapuis B, Matthes T. Expression of transcription factors Pu.1 Spi-B, Blimp-1, BSAP and OcT2 in normal human plasma cells and in multiple myeloma cells. Br J Haematol 2002; 116:429-35.
139. Saito T, Chiba S, Ichikawa M et al. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity 2003; 18:675-85.
140. Thomas MD, Kremer CS, Ravichandran KS, Rajewsky K, Bender TP. C-Myb is critical for B cell development and maintenance of follicular B cells. Immunity 2005; 23:275-86.
141. Golay J, Luppi M, Songia S et al. Expression of A-myb, but not c-myb and B-myb, is restricted to Burkitt's lymphoma, sIg+ B acute lymphoblastic leukemia and a subset of chronic lymphocytic leukemias. Blood 1996; 87:1900-11.
142. Xiao C, Calado DP, Galler G et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007; 131:146-59.
143. Wang M, Tan LP, Dijkstra MK et al. miRNA analysis in B cell chronic lymphocytic leukemia: proliferation centers characterized by low miR-150 and high BIC/miR-155 expression. J Pathol 2008; 215:13-20.
144. Tang LP, Wang M, Robertus JL et al. miRNA profiling of B cell subsets: specific miRNA profile for germinal center B cells with variation between centroblast and centrocytes. Lab Invest 2009; 89:708-76.
145. Ochai K, Maienschein-Cline M, Simonetti G et al. Transcriptional regulation of germinal center B cells and plasma cell fates by dynamical control of IRF4. Immunity 2013; 38:918-29.
146. Havelange V, Pekarsky Y, Nakamura T, Palamarchuk A, Alder H, Rassenti L, Kipps T, Croce CM. IRF4 mutations in chronic lymphocytic leukemia. Blood 2011; 118:2827-9.
147. Chung-Che C, Lorek J, Sabath DE, Ying L, Chitambar CR, Logan B, Kampalath B, Cleveland RP. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B cell chronic lymphocytic leukemia. Blood 2002; 100:4671-5.
148. Alinikula J, Nera KP, Junttilla S, Lassila O. Alternate pathways for BCL6-mediated regulation of B cells to plasma cell differentiation. Eur J Immunol 2011; 41:2404-13.
149. Zhou Z, Li A, Wang Z, Pei F, Xia Q, Liu G, Ren Y, Hu Z. Blimp-1 siRNA inhibits B cell differentiation and prevents the development of lupus in mice. Hum Immunol 2013; 74:297-301.
150. Martinez A, Pittaluga S, Rudelius M et al. Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B cell lymphomas: a novel germinal center marker. Am J Surg Pathol 2008; 32:1190-200.
151. Nickerson KM, Christensen SR, Cullen JL, Meng W, Luning Prak ET, Shlomchik MJ. TLR9 promotes tolerance by restricting survival of anergic anti-DNA B cells, yet is also required for their activation. J Immunol 2013; 190:1447-56.
152. Miles K, Heaney J, Sibinska Z, Salter D, Savill J, Gray D, Gray M. A tolerogenic role for Toll-like receptor 9 is revealed by B-cell interaction with DNA complexes expressed on apoptotic cells. Proc Natl Acad Sci USA 2012; 109:887-92.
153. Tromp JM, Tonino SH, Elias JA et al. Dichotomy in NF-κB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. Oncogene 2010; 29:5071-82.
154. Bertrand FE, Eckfeldt CE, Lysholm AS, LeBien TW. Notch-1 and Notch-2 exhibit unique patterns of expression in human B-lineage cells. Leukemia 2000; 14:2095-102.
155. Thomas M, Calamito M, Srivastava B, Maillard I, Pear WS, Allman D. Notch activity synergizes with B-cell-receptor and CD40 signaling to enhance B-cell activation. Blood 2007; 109:3342-50.
156. Chavez JC, Sahakian E, Pinilla-Ibarz J. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia. Core Evid 2013; 8:37-45.
157. Kharfan-Dabaja MA, Wierda WG, Cooper LJ. Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors. Leukemia 2014; 28:507-17.
158. Cheng S, Ma J, Guo A et al. BTK inhibition targets in vivo CLL proliferation through its effects on B cell receptor signalling activity. Leukemia 2014; 28:649-47.